Revolutionising Drug Development: Key Takeaways from the ICON Biotech Survey
In the dynamic landscape of biotechnology, ICON’s recent survey of over 100 leaders from the biotech industry dissects the challenges and opportunities faced by biotech…
In the dynamic landscape of biotechnology, ICON’s recent survey of over 100 leaders from the biotech industry dissects the challenges and opportunities faced by biotech…
We’re in a new era of biotech, defined by the interplay between biology, data and AI. And it’s the enabling technologies — the connected instruments,…
Did you know that it takes approximately seven years to develop and bring a new drug to market? However, this time can be significantly reduced…
Smart analytics applied to real-world data are increasingly enabling companies to track adverse effects, while at the same time identifying opportunities for drug repurposing. ArisGlobal’s…
The breakneck pace of digital transformation spurred by COVID-19 continued to reshape the life sciences landscape in 2023. Rather than a single watershed moment, this…
Arriello’s Kate Coleman discusses how best to tackle the five key priorities for getting the most from your approach to quality and risk in 2024….
The new Third-Party Audit Report Library (3PARL®) consortium, founded by Rephine and Eurofins Healthcare, aims to set a benchmark for life sciences manufacturing supply chain…
In the intensely competitive clinical trial environment, the ability of sponsors to pay research sites consistently and transparently is a growing concern. Traditional methods are…
Highly manual processes, specific local market requirements, and tool usage inconsistencies have impeded global information visibility and flow, adding risk to key regulatory processes. More…
With the end of the year quickly approaching, you will likely see multiple articles on the key trends of 2023 and predictions for 2024 start…